Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO) and Mesoblast Limited (OtherMEOBF)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Thermo Fisher (TMO – Research Report) and Mesoblast Limited (MEOBF – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Thermo Fisher (TMO)
In a report released today, Daniel Brennan from TD Cowen maintained a Buy rating on Thermo Fisher, with a price target of $683.00. The company’s shares closed last Thursday at $592.16.
According to TipRanks.com, Brennan is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Thermo Fisher with a $678.58 average price target, which is a 15.8% upside from current levels. In a report released today, TipRanks – Google also reiterated a Buy rating on the stock with a $669.00 price target.
See the top stocks recommended by analysts >>
Mesoblast Limited (MEOBF)
Bell Potter analyst John Hester maintained a Buy rating on Mesoblast Limited today and set a price target of A$4.45. The company’s shares closed last Wednesday at $1.59.
Hester has an average return of
According to TipRanks.com, Hester is ranked #1008 out of 12040 analysts.
Currently, the analyst consensus on Mesoblast Limited is a Strong Buy with an average price target of $2.54.
